Leung, Ting Fan <br/><br/>
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.  [electronic resource] 

 -  Vaccine  01 2018 
 - 98-106 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1873-2518 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2017.11.034  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--administration & dosage<br/>Adolescent<br/>Aluminum Hydroxide--administration & dosage<br/>Antibodies, Viral--blood<br/>Antibody Formation--immunology<br/>B-Lymphocytes--immunology<br/>CD4-Positive T-Lymphocytes--immunology<br/>Child<br/>Cohort Studies<br/>Female<br/>Human papillomavirus 16--genetics<br/>Human papillomavirus 18--genetics<br/>Humans<br/>Immunity, Cellular<br/>Immunization--methods<br/>Immunization Schedule<br/>Immunogenicity, Vaccine<br/>Neutralization Tests<br/>Papillomaviridae--immunology<br/>Papillomavirus Infections--prevention & control<br/>Papillomavirus Vaccines--administration & dosage